## DXCM: DexCom, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.86 indicates fundamental undervaluation. Quality metrics strong (ROE 31%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($64.50)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. DXCM DEADLINE: DexCom, Inc. Investors Encouraged to Contact Kirby McInerney LLP Before Looming Deadline in Lawsuit**
- Source: FOX40 News | 20251210T010925 | Neutral | Relevance: 100%
-  Investors in DexCom, Inc. (NASDAQ:DXCM) are urged to contact Kirby McInerney LLP regarding a securities fraud class action lawsuit, with a lead plaintiff deadline of December 26, 2025. The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 glucose monitors, leading to inaccurate readings, health risks, and a decline in stock prices due to regulatory scrutiny and downgrades. The firm is seeking to represent investors who suffered losses during the period of January 8, 2024, through September 17, 2025.

**2. DexCom, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - DXCM**
- Source: KLAS 8 News Now | 20251211T130915 | Neutral | Relevance: 99%
-  The DJS Law Group has announced a class action lawsuit against DexCom, Inc. (NASDAQ: DXCM) for alleged securities law violations. The lawsuit claims DexCom made false and misleading statements to the market by implementing product changes without FDA authorization, leading to lowered reliability and health risks for users. Shareholders who purchased DXCM shares between July 26, 2024, and September 17, 2025, are encouraged to contact the firm to discuss their rights and potential lead plaintiff appointments.

**3. Levi & Korsinsky Releases SueWallSt Podcast on DexCom, Inc. (DXCM) Lawsuit**
- Source: KLAS 8 News Now | 20251210T074700 | Neutral | Relevance: 99%
-  Levi & Korsinsky, LLP has released a SueWallSt Podcast detailing a class action securities lawsuit filed against DexCom, Inc. (NASDAQ:DXCM). The lawsuit alleges that DexCom made material design changes to its G6 and G7 glucose monitoring products without FDA authorization, rendering them less reliable and potentially posing health risks to users. Investors who suffered losses due to alleged securities fraud between January 8, 2024, and September 17, 2025, are encouraged to contact the firm.

**4. Class Action Filing Announced by Pomerantz LLP Against DexCom, Inc. â€“ DXCM**
- Source: SiouxlandProud | 20251211T120825 | Neutral | Relevance: 99%
-  Pomerantz LLP has announced a class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) and its officers. The lawsuit alleges that DexCom made materially false and misleading statements regarding its continuous glucose monitoring systems, the G6 and G7, particularly concerning unauthorized design changes and overstated accuracy, which led to significant stock price drops on several occasions. Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, have until December 26, 2025, to seek appointment as lead plaintiff.

**5. Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now**
- Source: WJBF | 20251209T220753 | Neutral | Relevance: 99%
-  A class action lawsuit has been filed against DexCom, Inc. on behalf of investors who allegedly suffered financial losses due to securities fraud between January 8, 2024, and September 17, 2025. Investors are encouraged to contact Levi & Korsinsky for more information about joining the lawsuit.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $77 | $75 | +3% |
| 2025-12-02 | Morgan Stanley | $75 | $63 | +19% |
| 2025-11-25 | Evercore ISI Gr | $68 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | main | Buy |
| 2025-12-02 | Morgan Stanley | up | Overweight |
| 2025-11-25 | Evercore ISI Gr | init | In-Line |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.14M) |
| Sells | 3 ($0.45M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Tudor Investment Cor: 17.7% (+100.0%)
- Vanguard Group Inc: 12.7% (+2.4%)
- Blackrock Inc.: 10.0% (-0.5%)
- State Street Corpora: 4.3% (-0.0%)
- BAILLIE GIFFORD & CO: 4.1% (-4.9%)

### Key Risks

1. Long-term trend broken: trading 7.6% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +2.2% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.86 indicates undervaluation relative to growth. Quality metrics strong (ROE 31%, margin 16%). Analyst sentiment positive (2 raises, avg +11%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $27.0B |
| Beta | 1.51 |
| 52W Range | $54.11 - $93.25 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.86 |
| Forward P/E | 27.7 |
| Current P/E | 33.4 |
| YoY Growth | 20.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 5.3% to 7.5% (+2.2% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 87th percentile. MRS_5 at 3.2% confirms short-term momentum alignment. AM_20 at 9.7% shows strong absolute momentum above own 20MA. Outperforming sector by 9.8pp, stock-specific strength. Below SMA200 (0.92x), long-term trend not supportive. MACD histogram positive (0.92), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 7.45% (CS: 88) | Strong |
| RSI_14 | 68.6 | Neutral |
| MACD Histogram | 0.92 | Bullish |
| vs SMA20 | 1.097x | Above |
| vs SMA50 | 1.076x | Above |
| vs SMA200 | 0.924x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $68.94
- **Stop Loss:** $64.50 (6.4% risk)
- **Target:** $77.82 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 310
- **Position Value:** $21,371.40
- **Portfolio %:** 21.37%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-12 (Est: $0.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.57 | $0.61 | +7.5% |
| 2025Q2 | $0.44 | $0.48 | +8.2% |
| 2025Q1 | $0.33 | $0.32 | -2.6% |
| 2024Q4 | $0.50 | $0.45 | -9.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*